Chardan Capital Reiterates Their Buy Rating on Logicbio Therapeutics (LOGC)

By Carrie Williams

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Logicbio Therapeutics (LOGCResearch Report) today and set a price target of $20.00. The company’s shares closed last Thursday at $6.80.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 34.6% and a 69.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Logicbio Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00, which is a 192.4% upside from current levels. In a report issued on May 12, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.07 and a one-year low of $3.05. Currently, Logicbio Therapeutics has an average volume of 63.62K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.